Skip to main content

 Scientific publications

Oligorecurrent nodal prostate cancer: radiotherapy quality assurance of the randomized PEACE V-STORM phase II trial.

Authors : Achard V, Jaccard M, Vanhoutte F, Siva S, Heikkilä R, Dirix P, Liefhooghe N, Otte FX, Gomez-Iturriaga A, Berghen C, Shelan M, Conde-Moreno A, Campos FL, Papachristofilou A, Guckenberger M, Meersschout S, Putora PM, Zwahlen D, Couñago F, Scorsetti M, Eito C, Barrado M, Zapatero A, Muto P, Van De Voorde L, Lamanna G, Koutsouvelis N, Dipasquale G, Ost P, Zilli T
Year : 2022
Journal : Radiother Oncol

Lymphocyte-sparing pelvic radiotherapy for prostate cancer: An in-silico study.

Authors : Baré M, Poeta S, Fernandes P, Jourani Y, Otte FX, Van Brussel S, Van Gestel D, Van den Begin R
Year : 2022
Journal : Phys Imaging Radiat Oncol
Volume : 23
Pages : 127-133

Oligometastatic Disease Detection with <sup>68</sup>Ga-PSMA-11 PET/CT in Hormone-Sensitive Prostate Cancer Patients (HSPC) with Biochemical Recurrence after Radical Prostatectomy: Predictive Factors and Clinical Impact.

Authors : Artigas C, Diamand R, Shagera QA, Plouznikoff N, Fokoue F, Otte FX, Gil T, Peltier A, Van Gestel D, Flamen P
Year : 2021
Journal : Cancers (Basel)
Volume : 13

Evaluation of the XVI dual registration tool for image-guided radiotherapy in prostate cancer.

Authors : Sousa F, Jourani Y, Van den Begin R, Otte FX, Ridai S, Desle M, Ferreira A, Ahmimed R, van Klink-de Goeij MCM, Van Gestel D
Year : 2021
Journal : Tech Innov Patient Support Radiat Oncol
Volume : 18
Pages : 22-28

The Multicenter, Randomized, Phase 2 PEACE V-STORM Trial: Defining the Best Salvage Treatment for Oligorecurrent Nodal Prostate Cancer Metastases.

Authors : Zilli T, Dirix P, Heikkilä R, Liefhooghe N, Siva S, Gomez-Iturriaga A, Everaerts W, Otte FX, Shelan M, Mercier C, Achard V, Thon K, Stellamans K, Moon D, Conde-Moreno A, Papachristofilou A, Scorsetti M, Gückenberger M, Ameye F, Zapatero A, Van De Voorde L, López Campos F, Couñago F, Jaccard M, Spiessens A, Semac I, Vanhoutte F, Goetghebeur E, Reynders D, Ost P
Year : 2021
Journal : Eur Urol Focus
Volume : 7
Pages : 241-244

PEACE V - Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial.

Authors : De Bruycker A, Spiessens A, Dirix P, Koutsouvelis N, Semac I, Liefhooghe N, Gomez-Iturriaga A, Everaerts W, Otte FX, Papachristofilou A, Scorsetti M, Shelan M, Siva S, Ameye F, Guckenberger M, Heikkilä R, Putora PM, Zapatero A, Conde-Moreno A, Couñago F, Vanhoutte F, Goetghebeur E, Reynders D, Zilli T, Ost P
Year : 2020
Journal : BMC Cancer
Volume : 20
Pages : 406

Phase II open-label study investigating apalutamide in patients with biochemical progression after radical prostatectomy.

Authors : Dirix P, Strijbos M, den Mooter TV, Liefhooghe N, Bruwaene SV, Uvin P, Ghysel C, Ost D, Schatteman P, Bral S, Engels B, Van den Begin R, Otte FX, Roumeguere T, Palumbo S, Neybuch Y, Fonteyne V, Ost P, Dirix L
Year : 2020
Journal : Future Oncol
Volume : 16
Pages : 1083-1189

68Ga-PSMA PET/CT-based metastasis-directed radiotherapy for oligometastatic prostate cancer recurrence after radical prostatectomy.

Authors : Artigas C, Flamen P, Charlier F, Levillain H, Wimana Z, Diamand R, Albisinni S, Gil T, Velthoven Rv, Peltier A, Van Gestel D, Roumeguere T, Otte FX
Year : 2019
Journal : World J Urol
Volume : 37
Pages : 1535-1542

Sterotactic body radiotherapy (sbrt) and oligometastatic bladder cancer : about a case and review of the literature

Authors : Mane M, Benkhaled S, Van Gestel D, Otte FX
Year : 2019
Journal : ejpmr
Volume : 6(1)
Pages : 78-83

Clinical impact of 68 Ga-PSMA PET/CT in prostate cancer patients with rising PSA after treatment with curative intent: preliminary analysis of a multidisciplinary approach.

Authors : Albisinni S, Artigas C, Aoun F, Biaou I, Grosman J, Gil T, Hawaux E, Limani K, Otte FX, Peltier A, Sideris S, Sirtaine N, Flamen P, Van Velthoven R
Year : 2017
Journal : BJU Int
Volume : 120(2)
Pages : 197-203

Vertebral Hemangioma Mimicking Bone Metastasis in 68Ga-PSMA Ligand PET/CT.

Authors : Artigas C, Otte FX, Lemort M, Van Velthoven R, Flamen P
Year : 2017
Journal : Clin Nucl Med
Volume : 42
Pages : 368-370

Paget bone disease demonstrated on 68Ga-PSMA ligand PET/CT.

Authors : Artigas C, Alexiou J, Garcia C, Wimana Z, Otte FX, Gil T, Van Velthoven R, Flamen P
Year : 2016
Journal : Eur J Nucl Med Mol Imaging
Volume : 43(1)
Pages : 195-6